Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient?
Immunoglobulin (IG) replacement therapy has served as lifesaving treatment in primary immunodeficiency diseases (PID) for more than six decades. Approximately 70% of patients with PID require IG replacement to maintain their health during the course of disease. It is estimated that about one-third of IG products is used for replacement therapy in these patients. On the other hand, the introduction of newer IG preparations is continuing to improve and extend the quality of life in PID patients. Because of the options available including concentrations, formulations, osmolality, product stabilizers, sodium concentration, anti-infective activity, IgA content and pH, it is important to match the PID patient's complications with potential side effects associated with the composition of a particular IG product. The purpose of this review is to present the clinical differences of intravenous IG among the various preparations regarding PID patients.
a 1 Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.|b 2 Department of Laboratory Medicine, Division of Clinical Immunology, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden.
Hasssan
H
Abolhassani
a 1 Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Hossein
MH
Asgardoon
a 1 Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.|c 3 Department of Immunology, School of Medicine, and Molecular Immunology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Nima
N
Rezaei
b 2 Department of Laboratory Medicine, Division of Clinical Immunology, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden.
Lennart
L
Hammarstrom
a 1 Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Asghar
A
Aghamohammadi
D006801:Humans; D007070:Immunoglobulin A / Q000737:chemistry / Q000627:therapeutic use; D016756:Immunoglobulins, Intravenous / Q000737:chemistry / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy* / Q000276:immunology; D011788:Quality of Life
D007070:Immunoglobulin A; D016756:Immunoglobulins, Intravenous
formulations; intravenous immunoglobulin; primary immunodeficiency disease; risk factors